| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/30/2008 | EP1915160A2 Derivatives of monosaccharides for the treatment of copd and allergic rhinitis |
| 04/30/2008 | EP1915159A1 Use of megestrol acetate for the treatment of obstructive pulmonary diseases |
| 04/30/2008 | EP1915158A1 Use of tiotropium salts in the treatment of severe persistant asthma |
| 04/30/2008 | EP1915157A2 Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
| 04/30/2008 | EP1915156A2 Method of treating parturient placental mammals in order to reduce maternal and/or utirine exhaustion |
| 04/30/2008 | EP1915155A1 Dihydropteridinones in the treatment of respiratory diseases |
| 04/30/2008 | EP1915154A2 Combination of organic compounds |
| 04/30/2008 | EP1915153A2 Immediate release therapeutic systems for improved oral absorption of 7-[(e)-tert-butyloxyiminomethyl]camtothecin |
| 04/30/2008 | EP1915152A2 Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts |
| 04/30/2008 | EP1915151A2 Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors |
| 04/30/2008 | EP1915150A1 Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them |
| 04/30/2008 | EP1915149A2 Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| 04/30/2008 | EP1915147A1 Use of mglur5 (esp. afq056) in gi (esp. gerd) |
| 04/30/2008 | EP1915146A2 Novel 1-aryl-3-azabicycloý3.1.0¨hexanes: preparation and use to treat neuropsychiatric disorders |
| 04/30/2008 | EP1915145A1 Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| 04/30/2008 | EP1915144A2 Method to reduce oxidative damage and improve mitochondrial efficiency |
| 04/30/2008 | EP1915143A2 Arginase ii: a target treatment of aging heart and heart failure |
| 04/30/2008 | EP1915142A1 Composition comprising oleic acid and the use thereof |
| 04/30/2008 | EP1915141A1 Method of use of deacetylase inhibitors |
| 04/30/2008 | EP1915140A2 Novel use of peptide compounds for treating muscle pain |
| 04/30/2008 | EP1915138A2 Drug-surfactant complexes for sustained release |
| 04/30/2008 | EP1915134A2 Formulations for 7-(t-butoxy)iminomethyl camptothecin |
| 04/30/2008 | EP1915133A1 Oil-in-water-type emulsion for topical application in dermatology |
| 04/30/2008 | EP1915132A1 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin |
| 04/30/2008 | EP1915131A1 Process |
| 04/30/2008 | EP1915129A2 Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation |
| 04/30/2008 | EP1915055A2 Non-nucleoside reverse transcriptase inhibitors |
| 04/30/2008 | EP1915054A2 Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
| 04/30/2008 | EP1915053A2 Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| 04/30/2008 | EP1748764B1 An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production |
| 04/30/2008 | EP1736148A4 Medical emulsion of perfluororganic compounds and method for the production thereof |
| 04/30/2008 | EP1727814B1 Nucleoside analogues with antiviral activity |
| 04/30/2008 | EP1716118B1 Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases |
| 04/30/2008 | EP1713791B1 5-fluoro- and chloro-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |
| 04/30/2008 | EP1664079B1 Thiomorpholino steroid compounds, the use thereof for the preparation of meiosis-regulating medicaments and method for the preparation thereof |
| 04/30/2008 | EP1647599B1 Quantitative method for detecting yessotoxins in fishery products based on the activation caused by the toxin in cellular phosphodiesterase |
| 04/30/2008 | EP1631275B1 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
| 04/30/2008 | EP1615936A4 Phosphates of secondary alcohols |
| 04/30/2008 | EP1601664B1 Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders |
| 04/30/2008 | EP1597259B1 Nitrogen-substituted hexahydropyrazino 1,2-a pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments |
| 04/30/2008 | EP1586316B1 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| 04/30/2008 | EP1531805B1 Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 04/30/2008 | EP1511739B1 Polymorphs of valsartan |
| 04/30/2008 | EP1444248B1 Novel anti-inflammatory androstane derivatives - 17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha |
| 04/30/2008 | EP1425381B1 Emu-based formulations for wound treatment related application information |
| 04/30/2008 | EP1397161B1 Compounds comprising an analgesic molecule linked to a vector |
| 04/30/2008 | EP1372677B1 Use of compositions comprising sesquiterpene derivatives for the treatment of cancer |
| 04/30/2008 | EP1335725B1 Use of cci-779 as an antineoplastic agent |
| 04/30/2008 | EP1212063B9 Topical azathioprine for the treatment of oral autoimmune diseases |
| 04/30/2008 | EP1196156B1 Transnasal anticonvulsive compositions |
| 04/30/2008 | EP0981360B1 Method for preventing gastritis using amylin or amylin agonists |
| 04/30/2008 | DE202007011825U1 Pharmazeutische Dosierungsformen Pharmaceutical dosage forms |
| 04/30/2008 | DE112006000479T5 Präparat zur Behandlung von nicht infektiösen, entzündlichen Darmkrankheiten Preparation for the treatment of non-infectious, inflammatory bowel diseases |
| 04/30/2008 | DE112004002408B4 Verfahren zur Gewinnung einer angereicherten Population von siRNA-exprimierenden Zellen A process for obtaining an enriched population of siRNA-expressing cells |
| 04/30/2008 | DE102006050655A1 Pharmaceutical composition useful for treating allergic diseases comprises RNA and an allergen |
| 04/30/2008 | DE102006050558A1 Transdermal patch for administering norelgestromin has a matrix layer comprising norelgestromin, a silicone and diethylene glycol monoethyl ether, butanediol or propylene glycol |
| 04/30/2008 | DE102006050516A1 New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure |
| 04/30/2008 | DE102006050515A1 New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia |
| 04/30/2008 | DE102006050513A1 New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia |
| 04/30/2008 | DE102006050512A1 New substituted dihydropyrazole- and dihydrotriazole derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases and anemia |
| 04/30/2008 | DE102006050511A1 New substituted dihydrotriazolone compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat or prophylaxis e.g. heart insufficiency, anemia, chronic kidney diseases and renal failure |
| 04/30/2008 | DE102006050510A1 New substituted dihydropyrazolthione compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat or prevent e.g. heart insufficiency, anemia, chronic kidney diseases and renal failure |
| 04/30/2008 | CN101171266A Acerola fruit-derived pectin and use thereof |
| 04/30/2008 | CN101171257A Pyrrolobenzodiazepines compound |
| 04/30/2008 | CN101171256A Fused thiazole derivatives having affinity for the histamine h3 receptor |
| 04/30/2008 | CN101171254A Fused thieno[2,3-B]pyridine and thiazolo[5,4-B]pyridine compounds for inhibiting KSP kinesin activity |
| 04/30/2008 | CN101171253A Hydrocodone polymorphs |
| 04/30/2008 | CN101171252A Tetracyclic azapyrazinoindolines as 5-HT2 ligands |
| 04/30/2008 | CN101171250A Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
| 04/30/2008 | CN101171249A Method for producing indole derivative having piperidine ring |
| 04/30/2008 | CN101171248A 3-mono- and 3,5-disubstituted piperidine derivatives as renin inhibitors |
| 04/30/2008 | CN101171247A Pyrrole derivatives as DNA gyrase and topoisomerase inhibitors |
| 04/30/2008 | CN101171246A Stable micronized candesartan cilexetil and methods for preparing thereof |
| 04/30/2008 | CN101171245A Indolylamino quinazoline derivatives as antitumor agents |
| 04/30/2008 | CN101171244A Indazolylamino quinazoline derivatives as antitumor agents |
| 04/30/2008 | CN101171241A Chromen-4-one inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| 04/30/2008 | CN101171238A (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-HT receptor |
| 04/30/2008 | CN101171237A Method for preparation of optionally 2-substituted 1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids |
| 04/30/2008 | CN101171236A Antitumoral tetrahydro-pyrimidines |
| 04/30/2008 | CN101171235A Dipyrazoles as central nervous system agents |
| 04/30/2008 | CN101171234A Dihydropyridine derivatives |
| 04/30/2008 | CN101171231A Diacylglycerol acyltransferase inhibitors |
| 04/30/2008 | CN101171229A Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
| 04/30/2008 | CN101171228A Pregabalin free of isobutylglutaric acid and a process for preparation thereof |
| 04/30/2008 | CN101171227A Pregabalin free of lactam and a process for preparation thereof |
| 04/30/2008 | CN101171221A Novel salts of boswellic acids and selectively enriched boswellic acids and preparation processes for the same |
| 04/30/2008 | CN101171052A Compounds for inhibiting KSP kinesin activity |
| 04/30/2008 | CN101171036A Delivery of TIGECYCLINE in the presence of WARFARIN |
| 04/30/2008 | CN101171026A Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage |
| 04/30/2008 | CN101171018A Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| 04/30/2008 | CN101171017A Azithromycin powder composition for oral suspension |
| 04/30/2008 | CN101171016A Delivery of tigecycline in the presence of heparin |
| 04/30/2008 | CN101171015A Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 04/30/2008 | CN101171014A Pteridines useful as HCV inhibitors and methods for the preparation thereof |
| 04/30/2008 | CN101171013A Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis |
| 04/30/2008 | CN101171012A Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| 04/30/2008 | CN101171011A Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder |
| 04/30/2008 | CN101171010A Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| 04/30/2008 | CN101171009A Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands |
| 04/30/2008 | CN101171008A Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux |